Literature DB >> 17057790

Intravitreal clearance of moxifloxacin.

Mohan N Iyer1, Feng He, Theodore G Wensel, William F Mieler, Matthew S Benz, Eric R Holz.   

Abstract

PURPOSE: To study the clearance of a single dose of intravitreally injected moxifloxacin in rabbits.
METHODS: Intravitreal injections of 200 microg/0.1 mL of moxifloxacin were performed in rabbits. Four eyes per time interval after injection (1, 6, 12, 24, 36 hours) and three eyes at 48 hours were enucleated, immediately frozen, and placed at -80 degrees C. Ocular dissection and isolation of frozen vitreous were performed. Antibiotic assays were performed with use of high-performance liquid chromatography.
RESULTS: The concentration of intravitreal moxifloxacin showed an exponential decay with a half-life of 1.72 hours. The mean vitreous concentration was 120.49 +/- 49.23 microg/mL 1 hour after injection, which declined to 20.23 +/- 5.85 microg/mL at 6 hours and 1.06 +/- 0.81 microg/mL at 12 hours. The aqueous levels of moxifloxacin showed an exponential decay from 10 microg/mL at 1 hour after intravitreal injection to undetectable levels by 12 hours after injection.
CONCLUSIONS: Moxifloxacin clearance from the vitreous is rapid and consistent with previous clearance studies of ciprofloxacin. Given that the injected dose corresponds to several times the minimum inhibitory concentration at which 90% of isolates are inhibited (MIC90) of organisms commonly involved in endophthalmitis, and that therapeutic levels are present up to 12 hours after injection, intravitreal moxifloxacin may have a role in the treatment of endophthalmitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 17057790      PMCID: PMC1447561     

Source DB:  PubMed          Journal:  Trans Am Ophthalmol Soc        ISSN: 0065-9533


  25 in total

1.  Endogenous endophthalmitis secondary to vancomycin-resistant enterococci infection.

Authors:  Bita Esmaeli; Eric R Holz; M Amir Ahmadi; Richard A Krathen; Issam I Raad
Journal:  Retina       Date:  2003-02       Impact factor: 4.256

2.  Dissecting ocular tissue for intraocular drug studies.

Authors:  R Abel; G L Boyle
Journal:  Invest Ophthalmol       Date:  1976-03

3.  Emergence of vancomycin resistance in coagulase-negative staphylococci.

Authors:  R S Schwalbe; J T Stapleton; P H Gilligan
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

4.  Moxifloxacin efficacy and vitreous penetration in a rabbit model of Staphylococcus aureus endophthalmitis and effect on gene expression of leucotoxins and virulence regulator factors.

Authors:  Stéphane Bronner; François Jehl; Jean-Daniel Peter; Marie-Cécile Ploy; Corinne Renault; Pierre Arvis; Henri Monteil; Gilles Prevost
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

5.  Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates.

Authors:  A Speciale; R Musumeci; G Blandino; I Milazzo; F Caccamo; G Nicoletti
Journal:  Int J Antimicrob Agents       Date:  2002-02       Impact factor: 5.283

6.  Vitreous and aqueous penetration of orally administered gatifloxacin in humans.

Authors:  Seenu M Hariprasad; William F Mieler; Eric R Holz
Journal:  Arch Ophthalmol       Date:  2003-03

7.  Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.

Authors:  Regis P Kowalski; Deepinder K Dhaliwal; Lisa M Karenchak; Eric G Romanowski; Francis S Mah; David C Ritterband; Y Jerold Gordon
Journal:  Am J Ophthalmol       Date:  2003-09       Impact factor: 5.258

8.  Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens.

Authors:  Michelle C Callegan; Raul Ramirez; Scott T Kane; D Clay Cochran; Harold Jensen
Journal:  Adv Ther       Date:  2003 Sep-Oct       Impact factor: 3.845

9.  Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases.

Authors:  Matthew S Benz; Ingrid U Scott; Harry W Flynn; Nichard Unonius; Darlene Miller
Journal:  Am J Ophthalmol       Date:  2004-01       Impact factor: 5.258

10.  Vitreous and aqueous penetration of orally administered moxifloxacin in humans.

Authors:  Seenu M Hariprasad; Gaurav K Shah; William F Mieler; Leonard Feiner; Kevin J Blinder; Nancy M Holekamp; Hua Gao; Randall A Prince
Journal:  Arch Ophthalmol       Date:  2006-02
View more
  7 in total

Review 1.  A comprehensive insight on ocular pharmacokinetics.

Authors:  Vibhuti Agrahari; Abhirup Mandal; Vivek Agrahari; Hoang M Trinh; Mary Joseph; Animikh Ray; Hicheme Hadji; Ranjana Mitra; Dhananjay Pal; Ashim K Mitra
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

2.  Bilateral acute iris transillumination following systemic administration of antibiotics.

Authors:  Paris Tranos; Evangelos Lokovitis; Stelios Masselos; Nikolaos Kozeis; Magda Triantafylla; Nikolaos Markomichelakis
Journal:  Eye (Lond)       Date:  2018-03-02       Impact factor: 3.775

Review 3.  Recent perspectives on the delivery of biologics to back of the eye.

Authors:  Mary Joseph; Hoang M Trinh; Kishore Cholkar; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Deliv       Date:  2016-09-06       Impact factor: 6.648

4.  Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives.

Authors:  M Kernt; A Kampik
Journal:  Clin Ophthalmol       Date:  2010-03-24

Review 5.  A Review of Antimicrobial Therapy for Infectious Uveitis of the Posterior Segment.

Authors:  Ahmed B Sallam; Kyle A Kirkland; Richard Barry; Mohamed Kamel Soliman; Tayyeba K Ali; Sue Lightman
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2018

6.  Toxicities of and inflammatory responses to moxifloxacin, cefuroxime, and vancomycin on retinal vascular cells.

Authors:  Hitomi Miyake; Dai Miyazaki; Yumiko Shimizu; Shin-Ichi Sasaki; Takashi Baba; Yoshitsugu Inoue; Kazuki Matsuura
Journal:  Sci Rep       Date:  2019-07-05       Impact factor: 4.379

Review 7.  Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations.

Authors:  Rubén Varela-Fernández; Victoria Díaz-Tomé; Andrea Luaces-Rodríguez; Andrea Conde-Penedo; Xurxo García-Otero; Asteria Luzardo-Álvarez; Anxo Fernández-Ferreiro; Francisco J Otero-Espinar
Journal:  Pharmaceutics       Date:  2020-03-16       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.